viewCardiex Ltd

CardieX subsidiary granted European patent for unique SphygmoCor blood pressure technology

Patent EP2566387 has been granted by the European Patent Office to protect the company’s intellectual property surrounding its SphygmoCor technology used in cuff-based brachial blood pressure devices.

Cardiex Ltd - Cardiex subsidiary granted European patent for its unique SphygmoCor blood pressure technology
The new patent is in force until March 2034

CardieX Ltd (ASX:CDX) subsidiary ATCOR has been granted a new patent by the European Patent Office (EPO) to protect the intellectual property (IP) for the company’s proprietary SphygmoCor technology used in cuff-based blood pressure devices.

EPO Patent Number EP2566387 further protects the company’s IP in relation to the measurement of a whole central blood pressure waveform with cardiovascular features using a brachial cuff.

Shares have been as much as 24% higher to 6 cents intra-day and have climbed from 2 cents at the market close on June 29.

“Unique technology”

Examining officers from the EPO specifically referenced the substantial differences in respect of any other existing patents when granting the new patent to ATCOR, demonstrating the unique nature of the technology.

CardieX CEO and managing director Craig Cooper said: “We are very pleased to be granted this new patent to protect our IP in Europe.

“Of great significance is the findings of the examining officers from the EPO which were similar to the findings we received from examiners in the US in 2016 - that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology.”

Patent coverage

Patent EP2566387 specifically covers non-invasively estimating the heart’s pressure and pressure waveform with features related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure.

The patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease which otherwise would require an invasive procedure.

The granting of the European patent follows similar patents already granted to the company in the United States and Japan with the new European patent in force until 2034.

Quick facts: Cardiex Ltd

Price: 0.048 AUD

Market: ASX
Market Cap: $40.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiex Ltd named herein, including the promotion by the Company of Cardiex Ltd in any Content on the Site, the Company receives from said...


CardieX Limited signs disruptive deal with Chinese medical device company Andon

CardieX Limited (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive with news the company has entered a co-development and commercial partnership agreement with Andon. Andon is one of China’s largest manufacturers of home-use medical electronic devices. Cooper talks about the deal...

on 9/9/20

2 min read